

Werner B F Brouwer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2622704/publications.pdf>

Version: 2024-02-01

182
papers

7,851
citations

50276

46
h-index

64796

79
g-index

186
all docs

186
docs citations

186
times ranked

7980
citing authors

#	ARTICLE	IF	CITATIONS
1	Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. <i>European Journal of Health Economics</i> , 2020, 21, 977-982.	2.8	760
2	The CarerQol instrument: A new instrument to measure care-related quality of life of informal caregivers for use in economic evaluations. <i>Quality of Life Research</i> , 2006, 15, 1005-1021.	3.1	298
3	The iMTA Productivity Cost Questionnaire. <i>Value in Health</i> , 2015, 18, 753-758.	0.3	298
4	Welfarism vs. extra-welfarism. <i>Journal of Health Economics</i> , 2008, 27, 325-338.	2.7	260
5	Discounting in Economic Evaluations. <i>Pharmacoeconomics</i> , 2018, 36, 745-758.	3.3	210
6	Productivity losses without absence: measurement validation and empirical evidence. <i>Health Policy</i> , 1999, 48, 13-27.	3.0	199
7	Need for differential discounting of costs and health effects in cost effectiveness analyses. <i>BMJ: British Medical Journal</i> , 2005, 331, 446-448.	2.3	171
8	Process utility from providing informal care: the benefit of caring. <i>Health Policy</i> , 2005, 74, 85-99.	3.0	158
9	Discounting and decision making in the economic evaluation of health-care technologies. <i>Health Economics (United Kingdom)</i> , 2011, 20, 2-15.	1.7	156
10	Caring for and caring about: Disentangling the caregiver effect and the family effect. <i>Journal of Health Economics</i> , 2010, 29, 549-556.	2.7	153
11	United but divided: Policy responses and people's perceptions in the EU during the COVID-19 outbreak. <i>Health Policy</i> , 2020, 124, 909-918.	3.0	147
12	Quality of life instruments for economic evaluations in health and social care for older people: A systematic review. <i>Social Science and Medicine</i> , 2014, 102, 83-93.	3.8	146
13	How to Estimate Productivity Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 2014, 32, 335-344.	3.3	144
14	Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel. , 1997, 6, 253-259.		136
15	How to Include Informal Care in Economic Evaluations. <i>Pharmacoeconomics</i> , 2013, 31, 1105-1119.	3.3	115
16	Patient and general public preferences for health states: A call to reconsider current guidelines. <i>Social Science and Medicine</i> , 2016, 165, 66-74.	3.8	110
17	Public views on principles for health care priority setting: Findings of a European cross-country study using Q methodology. <i>Social Science and Medicine</i> , 2015, 126, 128-137.	3.8	108
18	Discounting in economic evaluations: stepping forward towards optimal decision rules. <i>Health Economics (United Kingdom)</i> , 2007, 16, 307-317.	1.7	103

#	ARTICLE	IF	CITATIONS
19	Do Productivity Costs Matter?. <i>Pharmacoeconomics</i> , 2011, 29, 601-619.	3.3	102
20	How to govern the digital transformation of health services. <i>European Journal of Public Health</i> , 2019, 29, 7-12.	0.3	98
21	Reconciliation of Economic Concerns and Health Policy. <i>Pharmacoeconomics</i> , 2004, 22, 1097-1107.	3.3	95
22	Willingness to Pay for a Quality-Adjusted Life-Year: The Individual Perspective. <i>Value in Health</i> , 2010, 13, 1046-1055.	0.3	88
23	Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. <i>Disability and Rehabilitation</i> , 2012, 34, 988-996.	1.8	85
24	A Framework for Including Family Health Spillovers in Economic Evaluation. <i>Medical Decision Making</i> , 2016, 36, 176-186.	2.4	82
25	Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. <i>European Journal of Health Economics</i> , 2013, 14, 107-115.	2.8	80
26	Health Effects in Significant Others. <i>Medical Decision Making</i> , 2011, 31, 292-298.	2.4	77
27	A new test of the construct validity of the CarerQol instrument: measuring the impact of informal care giving. <i>Quality of Life Research</i> , 2011, 20, 875-887.	3.1	75
28	Measuring the impact of caregiving on informal carers: a construct validation study of the CarerQol instrument. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 173.	2.4	74
29	From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare. <i>Pharmacoeconomics</i> , 2016, 34, 1071-1074.	3.3	74
30	Productivity costs before and after absence from work: as important as common?. <i>Health Policy</i> , 2002, 61, 173-187.	3.0	73
31	When is it too expensive? Cost-effectiveness thresholds and health care decision-making. <i>European Journal of Health Economics</i> , 2019, 20, 175-180.	2.8	73
32	Give me a break!. <i>Health Policy</i> , 2008, 88, 73-87.	3.0	71
33	Unrelated Medical Costs in Life-Years Gained. <i>Pharmacoeconomics</i> , 2008, 26, 815-830.	3.3	68
34	Measuring Health Spillovers for Economic Evaluation: A Case Study in Meningitis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1529-1544.	1.7	68
35	A Dollar Is a Dollar Is a Dollar—or Is It?. <i>Value in Health</i> , 2006, 9, 341-347.	0.3	63
36	A Discrete Choice Experiment to Obtain a Tariff for Valuing Informal Care Situations Measured with the CarerQol Instrument. <i>Medical Decision Making</i> , 2014, 34, 84-96.	2.4	63

#	ARTICLE	IF	CITATIONS
37	Capabilities and quality of life in Dutch psycho-geriatric nursing homes: an exploratory study using a proxy version of the ICECAP-O. <i>Quality of Life Research</i> , 2012, 21, 801-812.	3.1	59
38	Acceptability of less than perfect health states. <i>Social Science and Medicine</i> , 2005, 60, 237-246.	3.8	56
39	Treatment for Sleep Problems in Children with Autism and Caregiver Spillover Effects. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 3613-3623.	2.7	56
40	Looking back and moving forward: On the application of proportional shortfall in healthcare priority setting in the Netherlands. <i>Health Policy</i> , 2018, 122, 621-629.	3.0	55
41	The Relationship between Productivity and Health-Related QOL. <i>Pharmacoeconomics</i> , 2005, 23, 209-218.	3.3	54
42	Sustained informal care: The feasibility, construct validity and test-retest reliability of the CarerQol-instrument to measure the impact of informal care in long-term care. <i>Aging and Mental Health</i> , 2011, 15, 1018-1027.	2.8	54
43	The influence of subjective life expectancy on health state valuations using a 10 year TTO. <i>Health Economics (United Kingdom)</i> , 2009, 18, 549-558.	1.7	51
44	Should I stay or should I go? Waiting lists and cross-border care in the Netherlands. <i>Health Policy</i> , 2003, 63, 289-298.	3.0	50
45	Expectations regarding length and health related quality of life: Some empirical findings. <i>Social Science and Medicine</i> , 2005, 61, 1083-1094.	3.8	50
46	Too Important to Ignore. <i>Pharmacoeconomics</i> , 2006, 24, 39-41.	3.3	50
47	The Value of a QALY: Individual Willingness to Pay for Health Gains Under Risk. <i>Pharmacoeconomics</i> , 2014, 32, 75-86.	3.3	50
48	Severity-Adjusted Probability of Being Cost Effective. <i>Pharmacoeconomics</i> , 2019, 37, 1155-1163.	3.3	50
49	VALUING QALY GAINS BY APPLYING A SOCIETAL PERSPECTIVE. <i>Health Economics (United Kingdom)</i> , 2013, 22, 1272-1281.	1.7	49
50	The Inclusion of Spillover Effects in Economic Evaluations: Not an Optional Extra. <i>Pharmacoeconomics</i> , 2019, 37, 451-456.	3.3	48
51	Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US. <i>Pharmacoeconomics</i> , 2017, 35, 469-478.	3.3	46
52	GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. <i>Journal of Health Economics</i> , 2012, 31, 158-168.	2.7	45
53	Inquiry into the Relationship between Equity Weights and the Value of the QALY. <i>Value in Health</i> , 2012, 15, 1119-1126.	0.3	43
54	Unpaid work in health economic evaluations. <i>Social Science and Medicine</i> , 2015, 144, 127-137.	3.8	42

#	ARTICLE	IF	CITATIONS
55	Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis. <i>Health Economics (United Kingdom)</i> , 2016, 25, 237-248.	1.7	41
56	Risk communication during COVID-19: A descriptive study on familiarity with, adherence to and trust in the WHO preventive measures. <i>PLoS ONE</i> , 2021, 16, e0250872.	2.5	41
57	Quality of Life of Nursing Home Residents with Dementia: Validation of the German Version of the ICECAP-O. <i>PLoS ONE</i> , 2014, 9, e92016.	2.5	41
58	Children with an Autism Spectrum Disorder and Their Caregivers: Capturing Health-Related and Care-Related Quality of Life. <i>Journal of Autism and Developmental Disorders</i> , 2020, 50, 263-277.	2.7	40
59	A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs. <i>European Journal of Health Economics</i> , 2016, 17, 391-402.	2.8	39
60	A cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending. <i>Health Economics (United Kingdom)</i> , 2019, 28, 87-100.	1.7	39
61	Time Is Money: Investigating the Value of Leisure Time and Unpaid Work. <i>Value in Health</i> , 2018, 21, 1428-1436.	0.3	38
62	The invisible hands made visible: recognizing the value of informal care in healthcare decision-making. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 557-561.	1.4	37
63	The influence of subjective expectations about length and quality of life on time trade-off answers. <i>Health Economics (United Kingdom)</i> , 2004, 13, 819-823.	1.7	36
64	The New Myth. <i>Pharmacoeconomics</i> , 2008, 26, 1-4.	3.3	34
65	Future Costs in Cost-Effectiveness Analyses: Past, Present, Future. <i>Pharmacoeconomics</i> , 2019, 37, 119-130.	3.3	33
66	Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2015, 33, 1289-1300.	3.3	31
67	The Challenge of Conditional Reimbursement: Stopping Reimbursement Can Be More Difficult Than Not Starting in the First Place!. <i>Value in Health</i> , 2017, 20, 118-125.	0.3	31
68	How to Calculate Indirect Costs in Economic Evaluations. <i>Pharmacoeconomics</i> , 1998, 13, 563-569.	3.3	30
69	The Perseverance Time of Informal Carers of Dementia Patients: Validation of a New Measure to Initiate Transition of Care at Home to Nursing Home Care. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 631-642.	2.6	30
70	A long life in good health: subjective expectations regarding length and future health-related quality of life. <i>European Journal of Health Economics</i> , 2016, 17, 577-589.	2.8	30
71	Blood donation in times of crisis: Early insight into the impact of COVID-19 on blood donors and their motivation to donate across European countries. <i>Vox Sanguinis</i> , 2021, 116, 1031-1041.	1.5	30
72	Lifestyle intervention: from cost savings to value for money. <i>Journal of Public Health</i> , 2010, 32, 440-447.	1.8	28

#	ARTICLE	IF	CITATIONS
73	Equity Weights for Priority Setting in Healthcare: Severity, Age, or Both?. Value in Health, 2019, 22, 1441-1449.	0.3	28
74	The missing link: on the line between C and E. Health Economics (United Kingdom), 2003, 12, 629-636.	1.7	26
75	Does the EQ-5D Reflect Lost Earnings?. Pharmacoeconomics, 2012, 30, 47-61.	3.3	25
76	Future unrelated medical costs need to be considered in cost effectiveness analysis. European Journal of Health Economics, 2019, 20, 1-5.	2.8	25
77	Subjective expectations regarding length and health-related quality of life in Hungary: results from an empirical investigation. Health Expectations, 2014, 17, 696-709.	2.6	24
78	Are some QALYs more equal than others?. European Journal of Health Economics, 2016, 17, 117-127.	2.8	24
79	QALYs without bias? Nonparametric correction of time trade-off and standard gamble weights based on prospect theory. Health Economics (United Kingdom), 2019, 28, 843-854.	1.7	24
80	The Value of Correcting Values: Influence and Importance of Correcting TTO Scores for Time Preference. Value in Health, 2010, 13, 879-884.	0.3	23
81	Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. Health Economics (United Kingdom), 2016, 25, 933-938.	1.7	23
82	Priority care for employees: A blessing in disguise?. , 1999, 8, 65-73.		22
83	Priority to End of Life Treatments? Views of the Public in the Netherlands. Value in Health, 2017, 20, 107-117.	0.3	22
84	Valid Outcome Measures in Care for Older People: Comparing the ASCOT and the ICECAP-O. Value in Health, 2017, 20, 936-944.	0.3	22
85	The burden of informal caregiving in Hungary, Poland and Slovenia: results from national representative surveys. European Journal of Health Economics, 2019, 20, 5-16.	2.8	22
86	Measuring Health Spillover Effects in Caregivers of Children with Autism Spectrum Disorder: A Comparison of the EQ-5D-3L and SF-6D. Pharmacoeconomics, 2019, 37, 609-620.	3.3	22
87	How do combinations of unhealthy behaviors relate to attitudinal factors and subjective health among the adult population in the Netherlands?. BMC Public Health, 2020, 20, 441.	2.9	22
88	The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems. Quality of Life Research, 2022, 31, 633-643.	3.1	22
89	Are all health gains equally important? An exploration of acceptable health as a reference point in health care priority setting. Health and Quality of Life Outcomes, 2015, 13, 79.	2.4	21
90	Rational expectations? An explorative study of subjective survival probabilities and lifestyle across Europe. Health Expectations, 2016, 19, 121-137.	2.6	21

#	ARTICLE	IF	CITATIONS
91	Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699.	0.3	21
92	The Monetary Value of Informal Care: Obtaining Pure Time Valuations Using a Discrete Choice Experiment. <i>Pharmacoeconomics</i> , 2019, 37, 531-540.	3.3	20
93	Willingness to pay for an early warning system for infectious diseases. <i>European Journal of Health Economics</i> , 2020, 21, 763-773.	2.8	20
94	Predicting productivity based on EQ-5D: an explorative study. <i>European Journal of Health Economics</i> , 2014, 15, 465-475.	2.8	19
95	From representing views to representativeness of views: Illustrating a new (Q2S) approach in the context of health care priority setting in nine European countries. <i>Social Science and Medicine</i> , 2016, 166, 205-213.	3.8	19
96	Views of older people in the Netherlands on wellbeing: A Q-methodology study. <i>Social Science and Medicine</i> , 2019, 240, 112535.	3.8	19
97	Can we fix it? Yes we can! But what? A new test of procedural invariance in TTO measurement. <i>Health Economics (United Kingdom)</i> , 2008, 17, 877-885.	1.7	18
98	The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument. <i>Molecular Genetics and Metabolism</i> , 2013, 110, 281-286.	1.1	18
99	Married with children—the influence of significant others in TTO exercises. <i>Health and Quality of Life Outcomes</i> , 2015, 13, 94.	2.4	18
100	Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients. <i>Value in Health</i> , 2021, 24, 1182-1192.	0.3	18
101	Discounting in decision making: the consistency argument revisited empirically. <i>Health Policy</i> , 2004, 67, 187-194.	3.0	16
102	The efficiency frontier approach to economic evaluation: will it help German policy making?. <i>Health Economics (United Kingdom)</i> , 2010, 19, 1128-1131.	1.7	16
103	Economics and public health: engaged to be happily married!. <i>European Journal of Public Health</i> , 2007, 17, 122-123.	0.3	15
104	Lifecycle evidence requirements for high-risk implantable medical devices: a European perspective. <i>Expert Review of Medical Devices</i> , 2020, 17, 993-1006.	2.8	15
105	Challenges with coverage with evidence development schemes for medical devices: A systematic review. <i>Health Policy and Technology</i> , 2020, 9, 146-156.	2.5	15
106	Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises. <i>Value in Health</i> , 2009, 12, 172-180.	0.3	14
107	Does living longer in good health facilitate longer working lives? The relationship between disability and working lives. <i>European Journal of Public Health</i> , 2015, 25, 791-795.	0.3	14
108	Who should receive treatment? An empirical enquiry into the relationship between societal views and preferences concerning healthcare priority setting. <i>PLoS ONE</i> , 2018, 13, e0198761.	2.5	14

#	ARTICLE	IF	CITATIONS
109	Does the ICECAP-O cover the physical, mental and social functioning of older people in the UK? Quality of Life Research, 2019, 28, 761-770.	3.1	14
110	Well-being of Older People (WOOP): Quantitative validation of a new outcome measure for use in economic evaluations. Social Science and Medicine, 2020, 259, 113109.	3.8	14
111	The Healthy Aging Index analyzed over 15 years in the general population: The Doetinchem Cohort Study. Preventive Medicine, 2020, 139, 106193.	3.4	13
112	What is it going to be, TTO or SG? A direct test of the validity of health state valuation. Health Economics (United Kingdom), 2020, 29, 1475-1481.	1.7	13
113	Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges. European Journal of Health Economics, 2021, 22, 1253-1273.	2.8	13
114	Productivity of Working at Home and Time Allocation Between Paid Work, Unpaid Work and Leisure Activities During a Pandemic. Pharmacoeconomics, 2022, 40, 77-90.	3.3	13
115	The Incorporation of Income and Leisure in Health State Valuations When the Measure Is Silent: An Empirical Inquiry into the Sound of Silence. Medical Decision Making, 2009, 29, 503-512.	2.4	12
116	Pharmacoeconomic Guidelines Should Prescribe Inclusion of Indirect Medical Costs! A Response to Grima et al.. Pharmacoeconomics, 2013, 31, 369-373.	3.3	12
117	The perseverance time of informal carers for people with dementia: results of a two-year longitudinal follow-up study. BMC Nursing, 2015, 14, 56.	2.5	12
118	The Impact of Hospital Payment Schemes on Healthcare and Mortality: Evidence from Hospital Payment Reforms in OECD Countries. Health Economics (United Kingdom), 2016, 25, 1005-1019.	1.7	12
119	Exploring a new method for deriving the monetary value of a QALY. European Journal of Health Economics, 2016, 17, 801-809.	2.8	12
120	What should we know about the person behind a TTO?. European Journal of Health Economics, 2018, 19, 1207-1211.	2.8	12
121	The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory. Value in Health, 2019, 22, 816-821.	0.3	12
122	Living up to expectations: Experimental tests of subjective life expectancy as reference point in time trade-off and standard gamble. Journal of Health Economics, 2020, 71, 102318.	2.7	12
123	Altruistic Preferences in Time Tradeoff. Medical Decision Making, 2016, 36, 187-198.	2.4	11
124	How to value safety in economic evaluations in health care? A review of applications in different sectors. European Journal of Health Economics, 2019, 20, 1041-1061.	2.8	11
125	How does participating in a deliberative citizens panel on healthcare priority setting influence the views of participants?. Health Policy, 2020, 124, 143-151.	3.0	11
126	Costs and benefits of early response in the Ebola virus disease outbreak in Sierra Leone. Cost Effectiveness and Resource Allocation, 2020, 18, 13.	1.5	11

#	ARTICLE	IF	CITATIONS
127	A validation study of the CarerQol instrument in informal caregivers of people with dementia from eight European countries. <i>Quality of Life Research</i> , 2021, 30, 577-588.	3.1	11
128	What works better for preference elicitation among older people? Cognitive burden of discrete choice experiment and case 2 best-worst scaling in an online setting. <i>Journal of Choice Modelling</i> , 2021, 38, 100265.	2.3	11
129	Content validation of the Well-being of Older People measure (WOOP). <i>Health and Quality of Life Outcomes</i> , 2021, 19, 200.	2.4	11
130	Instruments to assess quality of life in people with mental health problems: a systematic review and dimension analysis of generic, domain- and disease-specific instruments. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 249.	2.4	11
131	A QALY loss is a QALY loss is a QALY loss: a note on independence of loss aversion from health states. <i>European Journal of Health Economics</i> , 2019, 20, 419-426.	2.8	10
132	Estimating the monetary value of health and capability well-being applying the well-being valuation approach. <i>European Journal of Health Economics</i> , 2020, 21, 1235-1244.	2.8	10
133	Broadening the application of health technology assessment in the Netherlands: a worthwhile destination but not an easy ride?. <i>Health Economics, Policy and Law</i> , 2021, 16, 440-456.	1.8	10
134	The relative value of carer and patient quality of life: A person trade-off (PTO) study. <i>Social Science and Medicine</i> , 2022, 292, 114556.	3.8	10
135	“Back to the future” Influence of beliefs regarding the future on TTO answers. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 4.	2.4	9
136	Acceptable health and priority weighting: Discussing a reference-level approach using sufficientarian reasoning. <i>Social Science and Medicine</i> , 2017, 181, 158-167.	3.8	9
137	New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year. <i>European Journal of Health Economics</i> , 2018, 19, 277-291.	2.8	9
138	Some pain, no gain: experiences with the no-claim rebate in the Dutch health care system. <i>Health Economics, Policy and Law</i> , 2009, 4, 405-424.	1.8	8
139	Are people living with HIV less productive at work?. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2018, 30, 1265-1272.	1.2	8
140	A validation study of the ICECAP-O in informal carers of people with dementia from eight European Countries. <i>Quality of Life Research</i> , 2020, 29, 237-251.	3.1	8
141	Did the health of the Dutch population improve between 2001 and 2008? Investigating age- and gender-specific trends in quality of life. <i>European Journal of Health Economics</i> , 2015, 16, 801-811.	2.8	7
142	Estimating an anchored utility tariff for the well-being of older people measure (WOOP) for the Netherlands. <i>Social Science and Medicine</i> , 2022, 301, 114901.	3.8	7
143	A short note on measuring subjective life expectancy: survival probabilities versus point estimates. <i>European Journal of Health Economics</i> , 2017, 18, 7-12.	2.8	6
144	Indicators to facilitate the early identification of patients with major depressive disorder in need of highly specialized care: A concept mapping study. <i>Depression and Anxiety</i> , 2018, 35, 346-352.	4.1	6

#	ARTICLE	IF	CITATIONS
145	Integrating clinical and economic evidence in clinical guidelines: More needed than ever!. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 561-564.	1.8	6
146	Development of Population Tariffs for the CarerQol Instrument for Hungary, Poland and Slovenia: A Discrete Choice Experiment Study to Measure the Burden of Informal Caregiving. <i>Pharmacoeconomics</i> , 2020, 38, 633-643.	3.3	6
147	Validation of the Hungarian version of the CarerQol instrument in informal caregivers: results from a cross-sectional survey among the general population in Hungary. <i>Quality of Life Research</i> , 2021, 30, 629-641.	3.1	6
148	Coverage with evidence development for medical devices in Europe: Can practice meet theory?. <i>Health Economics (United Kingdom)</i> , 2022, 31, 179-194.	1.7	6
149	In Absence of Absenteeism: Some Thoughts on Productivity Costs in Economic Evaluations in a Post-corona Era. <i>Pharmacoeconomics</i> , 2022, 40, 7-11.	3.3	6
150	Psychometric evaluation of the Health-Risk Attitude Scale (HRAS-13): assessing the reliability, dimensionality and validity in the general population and a patient population. <i>Psychology and Health</i> , 2022, 37, 34-50.	2.2	5
151	Happy with Your Capabilities? Valuing ICECAP-O and ICECAP-A States Based on Experienced Utility Using Subjective Well-Being Data. <i>Medical Decision Making</i> , 2020, 40, 498-510.	2.4	5
152	Willingness to pay for quality and length of life gains in end of life patients of different ages. <i>Social Science and Medicine</i> , 2021, 279, 113987.	3.8	5
153	Estimating an exchange rate between care-related and health-related quality of life outcomes for economic evaluation: An application of the wellbeing valuation method. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2847-2857.	1.7	5
154	Life satisfaction: The role of domain-specific reference points. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2766-2779.	1.7	5
155	Caring for Children with an Autism Spectrum Disorder: Factors Associating with Health- and Care-Related Quality of Life of the Caregivers. <i>Journal of Autism and Developmental Disorders</i> , 2022, 52, 4665-4678.	2.7	5
156	Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries. <i>Health Economics (United Kingdom)</i> , 2022, , .	1.7	5
157	The decision tool unipolar depression (DTUD): a new measure to facilitate the early identification of patients with major depressive disorder in need of highly specialized care. <i>BMC Psychiatry</i> , 2019, 19, 179.	2.6	4
158	Don't forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. <i>Vaccine</i> , 2021, 39, 3834-3843.	3.8	4
159	Did the COVID-19 pandemic change the willingness to pay for an early warning system for infectious diseases in Europe?. <i>European Journal of Health Economics</i> , 2022, 23, 81-94.	2.8	4
160	Productivity Costs Measurement Through Quality of Life? A Response to the Recommendation of the Washington Panel. <i>Health Economics (United Kingdom)</i> , 1997, 6, 253-259.	1.7	4
161	Challenges in economic evaluations in obstetric care: a scoping review and expert opinion. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 1399-1407.	2.3	4
162	Primary care in cancer control: towards mature cancer care. <i>Lancet Oncology</i> , The, 2015, 16, 1226-1227.	10.7	3

#	ARTICLE	IF	CITATIONS
163	Acceptable health and ageing: results of a cross-sectional study from Hungary. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 346.	2.4	3
164	Costs and benefits of interventions aimed at major infectious disease threats: lessons from the literature. <i>European Journal of Health Economics</i> , 2020, 21, 1329-1350.	2.8	3
165	Distributional consequences of including survivor costs in economic evaluations. <i>Health Economics (United Kingdom)</i> , 2021, 30, 2606-2613.	1.7	3
166	Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers. <i>Value in Health</i> , 2022, 25, 222-229.	0.3	3
167	Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy. <i>Value in Health</i> , 2021, 24, 1470-1475.	0.3	3
168	Estimating the costs of non-medical consumption in life-years gained for economic evaluations. <i>Social Science and Medicine</i> , 2021, 289, 114414.	3.8	3
169	Mixed evidence for the compression of morbidity hypothesis for smoking elimination—a systematic literature review. <i>European Journal of Public Health</i> , 2021, 31, 409-417.	0.3	3
170	The evaluation of lifestyle interventions in the Netherlands. <i>Health Economics, Policy and Law</i> , 2012, 7, 243-261.	1.8	2
171	Peer effects in health valuation: the relation between rating of contemporaries' health and own health. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 148.	2.4	2
172	Performance-based risk-sharing agreements in renal care: current experience and future prospects. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 197-210.	1.4	2
173	Trust me; I know what I am doing investigating the effect of choice list elicitation and domain-relevant training on preference reversals in decision making for others. <i>European Journal of Health Economics</i> , 2021, 22, 679-697.	2.8	2
174	The value of health—Empirical issues when estimating the monetary value of a quality-adjusted life year based on well-being data. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1849-1870.	1.7	2
175	I costi sanitari indiretti (non correlati) durante gli anni di vita guadagnati. <i>Pharmacoeconomics Italian Research Articles</i> , 2009, 11, 55-70.	0.2	1
176	Una panoramica delle metodologie per la valutazione delle cure informali negli studi di economia sanitaria. <i>Pharmacoeconomics Italian Research Articles</i> , 2008, 10, 99-111.	0.2	0
177	Development and psychometric evaluation of the Transdiagnostic Decision Tool: matched care for patients with a mental disorder in need of highly specialised care. <i>BJPsych Open</i> , 2020, 6, .	0.7	0
178	Development and psychometric evaluation of the Decision Tool Anxiety Disorders, OCD and PTSD (DTAOP): Facilitating the early detection of patients in need of highly specialized care. <i>PLoS ONE</i> , 2021, 16, e0256384.	2.5	0
179	Title is missing!. , 2020, 15, e0238858.		0
180	Title is missing!. , 2020, 15, e0238858.		0

#	ARTICLE	IF	CITATIONS
181	Title is missing!. , 2020, 15, e0238858.		0
182	Title is missing!. , 2020, 15, e0238858.		0